Germany
· Delayed Price · Currency is EUR ImmunityBio Company Description
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 680 |
| CEO | Richard Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, Delaware 92121 United States | |
| Phone | 844 696 5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | 26CA |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Adcock | Chief Executive Officer |
| David Sachs | Chief Financial Officer |